Stockscreener 앱 받기
11.41
5.06%
0.55
시장 영업 전:
11.49
0.08
+0.70%
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Cantor Fitzgerald Predicts KROS FY2025 Earnings - MarketBeat
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Cantor Fitzgerald Downgrades Keros Therapeutics (KROS) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc.KROS - PR Newswire
Keros spikes as Teva deal takes effect; Cantor downgrades on trial setback - MSN
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros stock spikes as Teva deal takes effect (KROS:NASDAQ) - Seeking Alpha
Keros stock climbs on Takeda deal effectiveness - MSN
Keros Therapeutics stock rating cut to Neutral, cites dosing setback - MSN
Keros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to Neutral - MarketBeat
Keros Therapeutics seals $200M deal with Takeda - Investing.com
Keros Therapeutics stock rating cut to Neutral, cites dosing setback By Investing.com - Investing.com Canada
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - The Manila Times
Keros Therapeutics Secures $200M Upfront Payment in Major Takeda Licensing Deal for Elritercept - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround - Yahoo Finance
Keros Therapeutics’ (KROS) “Neutral” Rating Reiterated at Guggenheim - Defense World
The week in pharma: action, reaction and insight – week to January 17 - The Pharma Letter
Piper Sandler Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00 - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Wedbush - MarketBeat
Guggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks - MSN
Wedbush Downgrades Keros Therapeutics (KROS) - MSN
Scotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $41.00 - Defense World
Oppenheimer Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - Defense World
Piper Sandler cuts Keros stock target to $15, keeps Overweight - MSN
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) - Benzinga
Oppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat
Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer - MSN
Keros ends mid-stage trial for lead asset after adverse events - MSN
Keros stock price target cut on study termination - MSN
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN
Scotiabank maintained Keros Therapeutics at Sector Outperform By Investing.com - Investing.com UK
Keros Therapeutics (NASDAQ:KROS) Sets New 52-Week LowWhat's Next? - MarketBeat
Keros Therapeutics drops another Phase II cibotercept trial - The Pharma Letter
Keros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment Trials - MarketWatch
Keros Therapeutics (NASDAQ:KROS) Shares Down 8.9%What's Next? - MarketBeat
Keros Therapeutics stock falls after trial halt By Investing.com - Investing.com Australia
Keros Therapeutics stock falls after trial halt - Investing.com
Keros stock slips as trial for lead asset ends (KROS:NASDAQ) - Seeking Alpha
Keros Therapeutics Halts Pulmonary Hypertension Treatment Trials Due to Adverse Effects - MarketWatch
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial - The Manila Times
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $75.00 - Defense World
Keros Therapeutics (NASDAQ:KROS) Hits New 12-Month LowHere's Why - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Trading Down 8.9%Here's What Happened - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Keros Therapeutics Updates on Clinical Trials and Safety - TipRanks
Keros Therapeutics (NASDAQ:KROS) Reaches New 1-Year LowShould You Sell? - MarketBeat
Keros Therapeutics stock hits 52-week low at $15.31 - Investing.com India
Keros Therapeutics stock hits 52-week low at $15.31 By Investing.com - Investing.com UK
(KROS) Trading Report - Stock Traders Daily
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc.KROS - Longview News-Journal
Keros Therapeutics stock hits 52-week low at $15.67 By Investing.com - Investing.com Nigeria
Keros Therapeutics (NASDAQ:KROS) Hits New 52-Week LowWhat's Next? - MarketBeat
Keros Therapeutics stock hits 52-week low at $15.67 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach Out - AccessWire
4.81%
자본화:
|
볼륨(24시간):